{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:57:24Z","timestamp":1791244644089,"version":"4.1.0"},"posted":{"date-parts":[[2023,5,25]]},"group-title":"Neurology","reference-count":69,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,5,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>The root causes of dementia are still largely unclear, and the medical community lacks highly effective preventive and therapeutic pharmaceutical agents for dementia despite large investments into their development. There is growing interest in the question if infectious agents play a role in the development of dementia, with herpesviruses attracting particular attention. To provide causal as opposed to merely correlational evidence on this question, we take advantage of the fact that in Wales eligibility for the herpes zoster vaccine (Zostavax) for shingles prevention was determined based on an individual\u2019s exact date of birth. Those born before September 2 1933 were ineligible and remained ineligible for life, while those born on or after September 2 1933 were eligible to receive the vaccine. By using country-wide data on all vaccinations received, primary and secondary care encounters, death certificates, and patients\u2019 date of birth in weeks, we first show that the percentage of adults who received the vaccine increased from 0.01% among patients who were merely one week too old to be eligible, to 47.2% among those who were just one week younger. Apart from this large difference in the probability of ever receiving the herpes zoster vaccine, there is no plausible reason why those born just one week prior to September 2 1933 should differ systematically from those born one week later. We demonstrate this empirically by showing that there were no systematic differences (e.g., in pre-existing conditions or uptake of other preventive interventions) between adults across the date-of-birth eligibility cutoff, and that there were no other interventions that used the exact same date-of-birth eligibility cutoff as was used for the herpes zoster vaccine program. This unique natural randomization, thus, allows for robust causal, rather than correlational, effect estimation. We first replicate the vaccine\u2019s known effect from clinical trials of reducing the occurrence of shingles. We then show that receiving the herpes zoster vaccine reduced the probability of a new dementia diagnosis over a follow-up period of seven years by 3.5 percentage points (95% CI: 0.6 \u2013 7.1, p=0.019), corresponding to a 19.9% relative reduction in the occurrence of dementia. Besides preventing shingles and dementia, the herpes zoster vaccine had no effects on any other common causes of morbidity and mortality. In exploratory analyses, we find that the protective effects from the vaccine for dementia are far stronger among women than men. Randomized trials are needed to determine the optimal population groups and time interval for administration of the herpes zoster vaccine to prevent or delay dementia, as well as to quantify the magnitude of the causal effect when more precise measures of cognition are used. Our findings strongly suggest an important role of the varicella zoster virus in the etiology of dementia.<\/jats:p>","DOI":"10.1101\/2023.05.23.23290253","type":"posted-content","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T13:40:11Z","timestamp":1685022011000},"source":"Crossref","is-referenced-by-count":15,"title":["Causal evidence that herpes zoster vaccination prevents a proportion of dementia cases"],"prefix":"10.64898","author":[{"given":"Markus","family":"Eyting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"He\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"He\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8878-5505","authenticated-orcid":false,"given":"Pascal","family":"Geldsetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2023052704500507000_2023.05.23.23290253v1.1","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(19)32599-1","article-title":"The scale and profile of global dementia research funding","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"2023052704500507000_2023.05.23.23290253v1.2","doi-asserted-by":"crossref","unstructured":"Cummings, J. L. , Morstorf, T. & Zhong, K . Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6, 37 (2014).","DOI":"10.1186\/alzrt269"},{"key":"2023052704500507000_2023.05.23.23290253v1.3","unstructured":"Cummings, J. et al. Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimers Dement (N Y) 8, e12295 (2022)."},{"key":"2023052704500507000_2023.05.23.23290253v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2022.12.006"},{"key":"2023052704500507000_2023.05.23.23290253v1.5","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3233\/JAD-160152","article-title":"Microbes and Alzheimer\u2019s Disease","volume":"51","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"2023052704500507000_2023.05.23.23290253v1.6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11910-018-0863-1","article-title":"Viral Hypothesis and Antiviral Treatment in Alzheimer\u2019s Disease","volume":"18","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2023052704500507000_2023.05.23.23290253v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.06.3040"},{"key":"2023052704500507000_2023.05.23.23290253v1.8","doi-asserted-by":"crossref","unstructured":"Itzhaki, R. F . Overwhelming Evidence for a Major Role for Herpes Simplex Virus Type 1 (HSV1) in Alzheimer\u2019s Disease (AD); Underwhelming Evidence against. Vaccines (Basel) 9, 679 (2021).","DOI":"10.3390\/vaccines9060679"},{"key":"2023052704500507000_2023.05.23.23290253v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.06.030"},{"key":"2023052704500507000_2023.05.23.23290253v1.10","doi-asserted-by":"crossref","unstructured":"Devanand, D. P. et al. Antiviral therapy: Valacyclovir Treatment of Alzheimer\u2019s Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial. BMJ Open 10, e032112 (2020).","DOI":"10.1136\/bmjopen-2019-032112"},{"key":"2023052704500507000_2023.05.23.23290253v1.11","doi-asserted-by":"crossref","unstructured":"Wu, X. et al. Adult Vaccination as a Protective Factor for Dementia: A Meta-Analysis and Systematic Review of Population-Based Observational Studies. Front Immunol 13, 872542 (2022).","DOI":"10.3389\/fimmu.2022.872542"},{"key":"2023052704500507000_2023.05.23.23290253v1.12","unstructured":"Hernan, M. A. & Robins, J. M. Causal Inference: What if. (Chapman & Hall\/CRC, 2020)."},{"key":"2023052704500507000_2023.05.23.23290253v1.13","doi-asserted-by":"crossref","unstructured":"Schnier, C. , Janbek, J. , Lathe, R. & Haas, J . Reduced dementia incidence after varicella zoster vaccination in Wales 2013-2020. Alzheimers Dement (N Y) 8, e12293 (2022).","DOI":"10.1002\/trc2.12293"},{"key":"2023052704500507000_2023.05.23.23290253v1.14","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac484"},{"key":"2023052704500507000_2023.05.23.23290253v1.15","first-page":"1495","article-title":"Past exposure to vaccines and subsequent risk of Alzheimer\u2019s disease","volume":"165","year":"2001","journal-title":"CMAJ"},{"key":"2023052704500507000_2023.05.23.23290253v1.16","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/jgs.17606","article-title":"Comparison of rates of dementia among older adult recipients of two, one, or no vaccinations","volume":"70","year":"2022","journal-title":"J Am Geriatr Soc"},{"key":"2023052704500507000_2023.05.23.23290253v1.17","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/30.3.590"},{"key":"2023052704500507000_2023.05.23.23290253v1.18","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/j.clgc.2021.05.001","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin Treatment Is Inversely Associated With the Risk of Developing Alzheimer Disease or Other Dementia Among Patients With Non-muscle-invasive Bladder Cancer","volume":"19","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"2023052704500507000_2023.05.23.23290253v1.19","doi-asserted-by":"crossref","unstructured":"Gofrit, O. N. et al. Bacillus Calmette-Gu\u00e9rin (BCG) therapy lowers the incidence of Alzheimer\u2019s disease in bladder cancer patients. PLoS One 14, e0224433 (2019).","DOI":"10.1371\/journal.pone.0224433"},{"key":"2023052704500507000_2023.05.23.23290253v1.20","doi-asserted-by":"crossref","first-page":"P1469","DOI":"10.1016\/j.jalz.2019.06.4108","article-title":"P4-436: Vaccination Against Pneumonia in the Elderly May Reduce Alzheimer\u2019s Risk","volume":"15","year":"2019","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2023052704500507000_2023.05.23.23290253v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jeconom.2007.05.001"},{"key":"2023052704500507000_2023.05.23.23290253v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.08.011"},{"key":"2023052704500507000_2023.05.23.23290253v1.23","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000138"},{"key":"2023052704500507000_2023.05.23.23290253v1.24","doi-asserted-by":"crossref","unstructured":"Venkataramani, A. S. , Bor, J. & Jena, A. B . Regression discontinuity designs in healthcare research. BMJ 352, i1216 (2016).","DOI":"10.1136\/bmj.i1216"},{"key":"2023052704500507000_2023.05.23.23290253v1.25","unstructured":"UK Health Security Agency. Shingles: guidance and vaccination programme. Shingles: guidance and vaccination programme https:\/\/www.gov.uk\/government\/collections\/shingles-vaccination-programme (2021)."},{"key":"2023052704500507000_2023.05.23.23290253v1.26","doi-asserted-by":"crossref","unstructured":"Pan, C. X. , Lee, M. S. & Nambudiri, V. E . Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review. Ther Adv Vaccines Immunother 10, 25151355221084536 (2022).","DOI":"10.1177\/25151355221084535"},{"key":"2023052704500507000_2023.05.23.23290253v1.27","unstructured":"Swansea University. SAIL Databank. https:\/\/saildatabank.com\/."},{"key":"2023052704500507000_2023.05.23.23290253v1.28","doi-asserted-by":"crossref","unstructured":"Ford, D. V. et al. The SAIL Databank: building a national architecture for e-health research and evaluation. BMC Health Serv Res 9, 157 (2009).","DOI":"10.1186\/1472-6963-9-157"},{"key":"2023052704500507000_2023.05.23.23290253v1.29","unstructured":"NHS Digital. Attribution Data Set GP-Registered Populations Scaled to ONS Population Estimates -2011. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/attribution-dataset-gp-registered-populations\/attribution-data-set-gp-registered-populations-scaled-to-ons-population-estimates-2011."},{"key":"2023052704500507000_2023.05.23.23290253v1.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"2023052704500507000_2023.05.23.23290253v1.31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer\u2019s disease facts and figures","volume":"18","author":"Alzheimer\u2019s Association","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2023052704500507000_2023.05.23.23290253v1.32","doi-asserted-by":"publisher","DOI":"10.1002\/ANA.25380"},{"key":"2023052704500507000_2023.05.23.23290253v1.33","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25123"},{"key":"2023052704500507000_2023.05.23.23290253v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-375678-7.00511-3"},{"key":"2023052704500507000_2023.05.23.23290253v1.35","unstructured":"Global Burden of Disease Project 2019. GBD Compare. http:\/\/vizhub.healthdata.org\/gbd-compare (2020)."},{"key":"2023052704500507000_2023.05.23.23290253v1.36","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268803001523"},{"key":"2023052704500507000_2023.05.23.23290253v1.37","doi-asserted-by":"crossref","unstructured":"Marra, F. , Parhar, K. , Huang, B. & Vadlamudi, N . Risk Factors for Herpes Zoster Infection: A Meta-Analysis. Open Forum Infect Dis 7, ofaa005 (2020).","DOI":"10.1093\/ofid\/ofaa005"},{"key":"2023052704500507000_2023.05.23.23290253v1.38","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/ene.14174","article-title":"Sex and gender differences in Alzheimer\u2019s disease: current challenges and implications for clinical practice: Position paper of the Dementia and Cognitive Disorders Panel of the European Academy of Neurology","volume":"27","year":"2020","journal-title":"Eur J Neurol"},{"key":"2023052704500507000_2023.05.23.23290253v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0032-9"},{"key":"2023052704500507000_2023.05.23.23290253v1.40","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000401"},{"key":"2023052704500507000_2023.05.23.23290253v1.41","unstructured":"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. https:\/\/www.nice.org.uk\/guidance\/ng97 (2018)."},{"key":"2023052704500507000_2023.05.23.23290253v1.42","unstructured":"Centers for Disease Control and Prevention. Archived CDC Vaccine Price List as of June 1, 2018. Adult Vaccine Price List https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/2018\/2018-06-01.html (2022)."},{"key":"2023052704500507000_2023.05.23.23290253v1.43","first-page":"930","article-title":"Costs of adult vaccination in medical settings and pharmacies: an observational study","volume":"20","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"2023052704500507000_2023.05.23.23290253v1.44","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M18-2347","article-title":"A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations","volume":"170","year":"2019","journal-title":"Ann Intern Med"},{"key":"2023052704500507000_2023.05.23.23290253v1.45","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2022.0315","article-title":"Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US","volume":"79","year":"2022","journal-title":"JAMA Neurol"},{"key":"2023052704500507000_2023.05.23.23290253v1.46","unstructured":"Lin, G. et al. Beta-Amyloid Antibodies for Early Alzheimer\u2019s Disease: Effectiveness and Value; Draft Evidence Report. https:\/\/icer.org\/assessment\/alzheimers-disease-2022\/#timeline (2022)."},{"key":"2023052704500507000_2023.05.23.23290253v1.47","doi-asserted-by":"crossref","unstructured":"Huo, Z. et al. Cost-effectiveness of pharmacological therapies for people with Alzheimer\u2019s disease and other dementias: a systematic review and meta-analysis. Cost Eff Resour Alloc 20, 19 (2022).","DOI":"10.1186\/s12962-022-00354-3"},{"key":"2023052704500507000_2023.05.23.23290253v1.48","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu918"},{"key":"2023052704500507000_2023.05.23.23290253v1.49","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwx245"},{"key":"2023052704500507000_2023.05.23.23290253v1.50","doi-asserted-by":"crossref","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","article-title":"Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination","volume":"9","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023052704500507000_2023.05.23.23290253v1.51","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4669"},{"key":"2023052704500507000_2023.05.23.23290253v1.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.016"},{"key":"2023052704500507000_2023.05.23.23290253v1.53","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00499-1"},{"key":"2023052704500507000_2023.05.23.23290253v1.54","first-page":"1","article-title":"United Kingdom: Health System Review","volume":"24","year":"2022","journal-title":"Health Syst Transit"},{"key":"2023052704500507000_2023.05.23.23290253v1.55","unstructured":"Digital Health and Care Wales. Welsh Demographic Service Dataset (WDSD). https:\/\/web.www.healthdatagateway.org\/dataset\/cea328df-abe5-48fb-8bcb-c0a5b6377446# (2022)."},{"key":"2023052704500507000_2023.05.23.23290253v1.56","unstructured":"Statistical Directorate. Welsh Index of Multiple Deprivation 2011: Summary Report. https:\/\/www.gov.wales\/welsh-index-multiple-deprivation-full-index-update-ranks-2011 (2011)."},{"key":"2023052704500507000_2023.05.23.23290253v1.57","unstructured":"SAIL Databank. Welsh Longitudinal General Practice Dataset (WLGP) - Welsh Primary Care. https:\/\/web.www.healthdatagateway.org\/dataset\/33fc3ffd-aa4c-4a16-a32f-0c900aaea3d2 (2023)."},{"key":"2023052704500507000_2023.05.23.23290253v1.58","doi-asserted-by":"publisher","DOI":"10.14236\/jhi.v19i3.811"},{"key":"2023052704500507000_2023.05.23.23290253v1.59","unstructured":"Digital Health and Care Wales. Patient Episode Database for Wales. Digital Health and Care Wales https:\/\/dhcw.nhs.wales\/information-services\/health-intelligence\/pedw-data-online\/ (2020)."},{"key":"2023052704500507000_2023.05.23.23290253v1.60","unstructured":"NHS England. OPCS Classification of Interventions and Procedures. https:\/\/www.datadictionary.nhs.uk\/supporting_information\/opcs_classification_of_intervention s_and_procedures.html (2023)."},{"key":"2023052704500507000_2023.05.23.23290253v1.61","unstructured":"World Health Organization. ICD-10 : international statistical classification of diseases and related health problems : tenth revision. https:\/\/apps.who.int\/iris\/handle\/10665\/42980 (2004)."},{"key":"2023052704500507000_2023.05.23.23290253v1.62","unstructured":"Digital Health and Care Wales. Outpatient Database for Wales (OPDW). https:\/\/web.www.healthdatagateway.org\/dataset\/d331159b-b286-4ab9-8b36-db39123ec229 (2022)."},{"key":"2023052704500507000_2023.05.23.23290253v1.63","unstructured":"Public Health Wales. Welsh Cancer Intelligence and Surveillance Unit (WCISU). Public Health Wales https:\/\/phw.nhs.wales\/services-and-teams\/welsh-cancer-intelligence-and-surveillance-unit-wcisu\/ (2023)."},{"key":"2023052704500507000_2023.05.23.23290253v1.64","unstructured":"Digital Health and Care Wales. Annual District Death Extract (ADDE). https:\/\/web.www.healthdatagateway.org\/dataset\/15cf4241-abad-4dcc-95b0-8cd7c02be999 (2023)."},{"key":"2023052704500507000_2023.05.23.23290253v1.65","doi-asserted-by":"crossref","unstructured":"Villamizar-Villegas, M. , Pinzon-Puerto, F. A. & Ruiz-Sanchez, M. A . A comprehensive history of regression discontinuity designs: An empirical survey of the last 60 years. Journal of Economic Surveys Epub ahead of print, (2022).","DOI":"10.1111\/joes.12461"},{"key":"2023052704500507000_2023.05.23.23290253v1.66","doi-asserted-by":"publisher","DOI":"10.1080\/07350015.2017.1366909"},{"key":"2023052704500507000_2023.05.23.23290253v1.67","doi-asserted-by":"publisher","DOI":"10.1093\/restud\/rdr043"},{"key":"2023052704500507000_2023.05.23.23290253v1.68","doi-asserted-by":"publisher","DOI":"10.3982\/ECTA11757"},{"key":"2023052704500507000_2023.05.23.23290253v1.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jeconom.2007.05.005"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.05.23.23290253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:34:22Z","timestamp":1768505662000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.05.23.23290253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":69,"URL":"https:\/\/doi.org\/10.1101\/2023.05.23.23290253","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41586-025-08800-x","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.1162\/2e3983f5.dcaf9110","asserted-by":"object"},{"id-type":"doi","id":"10.1162\/2e3983f5.63d07c64","asserted-by":"object"},{"id-type":"doi","id":"10.1162\/2e3983f5.5075b345","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2023,5,25]]},"subtype":"preprint"}}